- Home
- ALNY vs TAK Comparison
ALNY vs TAK Comparison
Compare ALNY & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- TAK
- Stock Information
- Founded
- ALNY 2002
- TAK 1781
- Country
- ALNY United States
- TAK Japan
- Employees
- ALNY N/A
- TAK N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- ALNY Health Care
- TAK Health Care
- Exchange
- ALNY Nasdaq
- TAK Nasdaq
- Market Cap
- ALNY 42.9B
- TAK 47.5B
- IPO Year
- ALNY 2004
- TAK N/A
- Fundamental
- Price
- ALNY $343.69
- TAK $13.90
- Analyst Decision
- ALNY Strong Buy
- TAK
- Analyst Count
- ALNY 25
- TAK 0
- Target Price
- ALNY $347.75
- TAK N/A
- AVG Volume (30 Days)
- ALNY 869.5K
- TAK 3.4M
- Earning Date
- ALNY 07-31-2025
- TAK 07-30-2025
- Dividend Yield
- ALNY N/A
- TAK 3.79%
- EPS Growth
- ALNY N/A
- TAK N/A
- EPS
- ALNY N/A
- TAK 0.45
- Revenue
- ALNY $2,348,099,000.00
- TAK $30,595,075,281.00
- Revenue This Year
- ALNY $32.73
- TAK $1.01
- Revenue Next Year
- ALNY $31.50
- TAK $1.04
- P/E Ratio
- ALNY N/A
- TAK $62.56
- Revenue Growth
- ALNY 17.21
- TAK 7.45
- 52 Week Low
- ALNY $205.87
- TAK $12.80
- 52 Week High
- ALNY $333.70
- TAK $15.53
- Technical
- Relative Strength Index (RSI)
- ALNY 64.89
- TAK 38.22
- Support Level
- ALNY $323.74
- TAK $14.29
- Resistance Level
- ALNY $332.19
- TAK $14.86
- Average True Range (ATR)
- ALNY 7.50
- TAK 0.18
- MACD
- ALNY 0.31
- TAK -0.05
- Stochastic Oscillator
- ALNY 94.08
- TAK 2.60
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.